Dyadic, Biotech Stock Review

Dyadic (DYAI) Highlights.

"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and...

Adding Citius (CTXR) $0.55 to Watch List.

Best Presentation at Dawson James Conference. We attended the Dawson James Conference on October 29th, which had over 20...
Dyadic, Biotech Stock Review

Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.

Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.
candida auris, citius pharma, biotech stock review

Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...

Latest article

Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

GeoVax (GOVX) Launches Vaccine Manufacturing System.

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...

Experts From Harvard, Scripps Research Institute, the University Hospital Zürich, and the Former Chief...

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody...